The Relative Strength (RS) Rating for Labcorp Holdings entered a higher percentile Wednesday, as it got a lift from 70 to 76.
IBD's unique RS Rating identifies technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock's price action over the trailing 52 weeks stacks up against all the other stocks in our database.
Decades of market research reveals that the market's biggest winners typically have an 80 or better RS Rating as they launch their biggest runs. See if Labcorp Holdings can continue to rebound and hit that benchmark.
How To Invest In Stocks In Both Bull And Bear Markets
Labcorp Holdings is trying to complete a double bottom with a 242.61 buy point. See if the stock can break out in heavy trade.
While earnings growth decreased in the company's most recent quarterly report from 15% to 4%, the top line grew 7%, up from 6% in the prior report. Keep an eye out for the company's next round of numbers on or around Feb. 6.
The company holds the No. 10 rank among its peers in the Medical-Services industry group. Castle Biosciences, Hims & Hers Health and NeoGenomics are among the top 5 highly rated stocks within the group.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
